Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatmen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Kussmann, Manuel, Obermueller, Markus, Berndl, Florian, Reischer, Veronika, Veletzky, Luzia, Burgmann, Heinz, Poeppl, Wolfgang
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018549/
https://ncbi.nlm.nih.gov/pubmed/29941909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-28006-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky